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AbstrACt
Introduction Cumulative network meta-analysis 
(NMA) is a method to provide a global comparison of 
multiple treatments with real-time update to evidence 
users. Several studies investigated the ranking of 
cumulative NMA and the recommendations of practice 
guidelines. However, to the best of our knowledge, no 
study has evaluated the cumulative NMA ranking and 
prescription patterns. Here, we present a protocol for 
a meta-epidemiological investigation to compare the 
results of cumulative NMA with the recommendations in 
postmenopausal osteoporosis practice guidelines and with 
the actual prescriptions.
Method and analysis We will use the data of primary 
trials from the upcoming postmenopausal osteoporosis 
clinical practice guideline of the Endocrine Society. 
We will conduct cumulative NMA using all eligible 
trials and generate hierarchy of treatment rankings by 
using the surface under the cumulative ranking curve. 
We will search practice guidelines in relevant society 
websites. Two review authors will extract the practice 
recommendations. We will use data from the Medical 
Expenditures Panel Survey, a US representative sample 
of the non-institutionalised population, to determine the 
prescription patterns.
Ethics and dissemination Because all data will be 
retrieved from public databases, institutional review board 
approval is not required. We will publish our findings 
in a peer-reviewed journal and present key findings at 
conferences.
trial registration number UMIN000031894: Pre-results.
IntroduCtIon 
Recommendations in clinical practice 
guidelines (CPGs) should be ‘informed by 
a systematic review (SR) of evidence and 
an assessment of the benefits and harms 
of alternative care options’.1 Incorporating 
SR and meta-analysis (MA) into CPGs has 
greatly improved the credibility of CPGs in 
the past decades.2–4 However, conventional 
pairwise MAs that compare two interven-
tions at a time is insufficient for analysing 
the increasing number of treatment options 
in a coherent manner because not all treat-
ment alternatives have been compared 
directly in randomised trials.5–7 Network 
MA (NMA) combines direct and indirect 
evidence and generates the relative effects 
of three or more treatment alternatives in a 
single analysis. Cumulative NMA can provide 
global comparisons of multiple treatment 
options with repeated updates.7 8 Moreover, 
because NMAs use both direct and indirect 
evidence, they can provide answers earlier 
than conventional pairwise MAs.8 
strengths and limitations of this study
 ► This study is novel because it will compare rankings 
of drugs based on cumulative network meta-analy-
sis with both clinical practice guideline recommen-
dations and actual prescriptions.
 ► This study will delineate the time  lag between the 
body of evidence and guideline recommendations, 
and actual practice.
 ► Physicians’ choice would be affected by reasons 
other than evidence about efficacy, which cannot be 
considered in this study.
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Whether successive revisions of CPGs in various 
fields of medicine have been able to incorporate such 
rigorous evidence updates remains an open question. 
One recent study compared the rankings by cumula-
tive NMAs and recommendations of CPGs for open-
angle glaucoma and found that cumulative NMAs can 
contribute to more timely recommendations than had 
traditionally been possible.9 This study did not intend 
to examine the influence of the updated evidence and 
the CPGs on the actual prescriptions by physicians for 
the disease. The translation of clinical knowledge from 
randomised controlled trials (RCTs) through cumula-
tive NMAs and CPGs to actual prescription patterns by 
physicians is at the heart of evidence-based practices 
and therefore deserves greater scrutiny.
Postmenopausal osteoporosis is a common disease 
worldwide and in the USA; its prevalence is increasing 
with the ageing of the populations.10 11 The US Food and 
Drug Administration (FDA) has approved 12 classes of 
drugs for this condition.12 Several US and international 
societies and organisations have developed CPGs for 
the use of these drugs,12–14 but the real-world prescrip-
tion patterns vary widely.15 This study aims to compare 
the results of cumulative NMAs with the recommenda-
tions in postmenopausal osteoporosis practice guide-
lines and with the actual prescription practices.
MEthods And AnAlysIs
sr and cumulative nMAs of osteoporosis drugs
Study identification and data extraction
We will retrieve eligible original articles and data from 
the upcoming postmenopausal osteoporosis CPG of the 
Endocrine Society. We will use a recently completed 
search for relevant studies (last search date: 7 July 2017) 
that we have conducted for the guideline. The inclu-
sion criteria are:
i. Parallel-group RCTs.
ii. Trials studied postmenopausal women with primary 
osteoporosis or osteopenia at risk of developing fra-
gility fractures.
iii. Trials evaluated commonly used medications includ-
ing bisphosphonates, teriparatide, selective oestro-
gen receptor modulators, denosumab, oestrogen with 
or without progesterone, calcitonin, lasofoxifene, 
strontium ranelate, tibolone or intact parathyroid 
hormone (1–84). We will also include nutritional sup-
plements commonly recommended for osteoporosis 
including calcium and vitamin D. Control conditions 
may include placebo, no treatment or treatment as 
usual.
iv. Trials must have evaluated the primary outcome of 
interest in this study, namely, new hip fractures at the 
time of the longest follow-up in the included studies. 
Hip fracture was designated as primary because of its 
clinical impact of patients’ prognosis.16
We did not limit language, geographical location or 
publication date.
Two of 10 review authors independently exam-
ined each title and abstract identified in the search 
to exclude obviously irrelevant reports, then inde-
pendently examine full‐text articles to determine eligi-
bility. If there were any disagreements, the same authors 
discussed disagreements; a third author helped reach 
consensus if necessary. The same independent pairs of 
reviewers also evaluated the risk of bias following the 
Cochrane risk of bias tool.17 They resolved any disagree-
ment through discussion of the two assessors or, where 
necessary, in consultation with a third assessor.
Statistical analyses
We will conduct random-effects cumulative NMAs of the 
identified network of trials at 5-year intervals (see below 
for Comparisons of NMA rankings, CPG recommenda-
tions and actual prescriptions).18 Each drug as well as 
each combination of drugs will be treated as a node in 
this network. We will assess the transitivity assumption of 
the whole data set in the final NMA; if confirmed, we will 
not validate it at every time point reanalysis. We will use 
a multilevel hierarchical model with components at the 
following levels: study, individual drug and drug class. 
This model accounts for the within-study correlation of 
multigroup trials and also incorporates class effect.19–21 
Given the clinical and methodological heterogeneity of 
the populations and methods among the included trials 
in NMAs, we will use the random-effects model in our 
primary analyses. We will examine the consistency of 
the total network through both local and global tests of 
inconsistency. We will test small study effects and publi-
cation bias using the comparison-adjusted funnel plot 
taking placebo as the common comparator.22
We will examine the hierarchy of treatment rankings 
by using the surface under the cumulative ranking curve 
(SUCRA).22 23 A SUCRA value can indicate a ranking of 
the treatment while accounting both for the location and 
the variance of all relative treatment effects. The larger the 
SUCRA value, the better the ranking of the treatment.22 23 
We will also show the relative treatment effects of all active 
medications in comparison with placebo in ranked forest 
plots. We will not adjust for multiple comparisons in succes-
sive NMAs as we are not interested in establishing superi-
ority or inferiority of particular comparisons.
We will use Stata V.15.1 (StataCorp to conduct NMAs.24 25 
We will conduct the cumulative NMA in a frequentist frame-
work using Stata, and therefore, no prior distributions and 
relevant sensitivity analyses will be employed.
Identification of practice guideline recommendations
We will search the website of Agency for Healthcare 
Research and Quality (AHRQ)’s National Guideline Clear-
inghouse,26 American Association of Clinical Endocri-
nologists,27 American College of Physicians,28 Endocrine 
Society29 and The North American Menopause Society30 
using the following term: ‘osteoporosis’. One author (YK) 
will select guidelines for the treatment of postmenopausal 
osteoporosis from US-based organisations because we will 
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evaluate the US prescriptions. Two of five independent 
authors (YK, YL, AO, MK and YT) will extract data from 
each guideline. We will extract publication year, developers, 
drug treatment recommendations and their strength, and 
whether the recommendations were based on SRs or not. 
We will resolve disagreements through discussion and, if 
necessary, though arbitration by another author (YK, YL, 
AO, MK or YT).
real-world prescriptions
Medical Expenditure Panel Survey (MEPS) is a survey from 
nationally representative samples of the US non-institu-
tionalised civilian population. MEPS uses sampling weights 
reflecting adjustments for survey non-response and popu-
lation totals from the Current Population Survey31 and can 
therefore be used to derive nationally representative esti-
mates. We will use the Household Component Files which 
contain detailed information about demographic informa-
tion and prescribed medicines for respondents.31 We will 
include all female respondents aged 50 years and older 
who have been classified as ‘206 osteoporosis’. The cut-off 
value of 50 is in accordance with previous reports.32 33 We 
will exclude those who have been classified as ‘202 rheuma-
toid arthritis and related disease’, because they may have 
steroid-induced osteoporosis.34 We will also exclude those 
who have been classified as ‘158 chronic renal failure’, 
because they would have mineral and bone disorders.35 We 
will also exclude those who have been classified as ‘cancer’ 
(the codes are from 11 to 44), because they sometimes have 
bone metastasis which need to be treated with bone modi-
fying agents.36
The prescription proportions and rankings will be deter-
mined by the 5-year prescription proportion of each drug 
category. The proprietary and non-proprietary names will 
be searched using the following terms from pharmacolog-
ical class of National Drug Code Directory37: Bisphospho-
nate (EPC), Parathyroid Hormone Analog (EPC), Selective 
Estrogen Receptor Modulators (MoA), RANK Ligand 
Inhibitor (EPC), Estrogen (EPC), Progestin (EPC), Calci-
tonin (EPC), Calcium (Chemical/Ingredient), Vitamin 
D2 Analog(EPC) and Vitamin D3 Analog (EPC).
The numerator will be the number of patients who were 
prescribed each specific drug within 5 years. The denom-
inator will be the number of patients who were female, 
over 50 years, and diagnosed as osteoporosis within the 
same 5 years. The greater proportion will mean the higher 
ranking.
We anticipate that we can start retrieving data in 
December 2018.
We will use Python V.3.6 (Python Software Foundation) 
and STATA V.15.1 (StataCorp) to handle data from MEPS.
Comparisons of nMA rankings, CPG recommendations and 
real-world prescriptions
We will compare results from cumulative NMAs with recom-
mendations by CPGs and with actual prescriptions at 5-year 
intervals. MEPS started in 1996. We, therefore, chose 1996 
as the first year of prescription ranking.
Because there is bound to be some time lag as randomised 
evidence is generated, synthesised, integrated into recom-
mendations and translated into practice, the time frame 
for the comparisons will be set as shown in table 1. First, 
because the median time from last search to publication of 
SRs has been found to be 8.0 months (range: 0–47), we will 
include trials published up to 1 year prior to conducting the 
cumulative NMA.38 As there should be no time lag between 
the latest evidence synthesis and the CPG recommenda-
tions, we expect the NMA results to be reflected in the CPGs 
published in the ensuing 5 years. In 2000 a meta-epidemio-
logical study showed a delay by 9.3 years between evidence 
review and its implementation.39 This delay may have been 
shortened in recent years.40 We will therefore compare the 
results from NMA and the CPG recommendations with 
actual prescriptions 1 or more years later than them.
This is a descriptive study. We will visually explore the 
differences between evidences from NMA, CPG and 
actual prescriptions. We will not conduct statistical tests 
for comparison.
In comparing cumulative NMA rankings based on 
best-available evidence in the world literature and the CPG 
recommendations and the prescriptions in USA, we will 
take into consideration the drug approval dates for osteo-
porosis by FDA as well as the dates when each drug became 
off-patent. To examine the influence of drug costs, we will 
tabulate the approval and off-patent date of each drug while 
on patent and also conduct a sensitivity analysis by limiting 
the analyses to patients with insurance.
Patient and public involvement
The study group developed this study protocol without 
patient involvement. This study will use only anonymised 
public data without new patient recruitment. We will dissem-
inate the results via web sites and social network services to 
patients with osteoporosis.
EthICs And dIssEMInAtIon
We will prepare the publication in accordance with 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses guideline41 and its adaptation for meta-ep-
idemiological studies.42 We will publish our findings in 
Table 1 Time frame for comparisons
Publication year 







2014 2015 2015–2017 − 
2009 2010 2010–2014 2011–2015
2004 2005 2005–2009 2006–2010
1999 2000 2000–2004 2001–2005
1994 1995 1995–1999 1996–2000
CPGs, clinical practice guidelines; NMA, network meta-analysis; 
RCTs, randomised controlled trials.
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a peer-reviewed journal and also may present them at 
conferences.
dIsCussIon
We have presented the study protocol to compare the 
results of cumulative NMA with the recommendations in 
CPGs, and with the actual prescriptions.
To our knowledge, this is the first effort to evaluate 
the influence of cumulative evidence to CPGs and 
physicians’ attitude simultaneously. By using cumula-
tive NMA, the real-time trend of cumulative evidence 
and comprehensive network of available treatments 
will be presented.6 7 By using the MEPS, it is possible to 
estimate the representative prescription trends in the 
USA.31
There are several limitations for this study. First, physi-
cians’ choice would be affected by reasons other than 
evidence, such as the policy of insurance companies or 
the marketing efforts of pharmaceutical company.43 44 
These factors are difficult to quantify and will warrant 
a separate study. Second, we should not prescribe teri-
paratide and bisphosphonate for long term because 
of their harm.45 In this study, we plan to compare the 
proportion of prescriptions in MEPS, which will there-
fore likely underestimate the rankings of the teri-
paratide and bisphosphonate in comparison with its 
incident prescriptions.
In conclusion, this study will provide useful empirical 
evidence to compare the results of cumulative NMA 
with the recommendations in CPGs and with the actual 
prescriptions. The expected findings will show the magni-
tude of the impact of comprehensive evidence in CPGs 
and real-world prescriptions.
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